148 related articles for article (PubMed ID: 31771770)
1. [Specificity of the management of metastatic renal cancer in the older patient].
Neuzillet Y; Albrand G; Caillet P; Paillaud E; Mongiat-Artus P
Prog Urol; 2019 Nov; 29(14):874-895. PubMed ID: 31771770
[TBL] [Abstract][Full Text] [Related]
2. [Geriatric specificities of localized renal cell carcinoma].
Mongiat-Artus P; Paillaud E; Caillet P; Albrand G; Neuzillet Y
Prog Urol; 2019 Nov; 29(14):865-873. PubMed ID: 31771769
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Mery B; Jones S; Vallard A; Rowinski E; Guillot A; Magné N
Bull Cancer; 2018 Dec; 105 Suppl 3():S235-S241. PubMed ID: 30595152
[TBL] [Abstract][Full Text] [Related]
4. [Management of metastatic renal cell carcinomass].
Rolley C; Aubert C; Baize N; Bigot P
Prog Urol; 2018 Nov; 28(14):777-782. PubMed ID: 30174169
[TBL] [Abstract][Full Text] [Related]
5. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
[TBL] [Abstract][Full Text] [Related]
6. Current management and future perspectives of metastatic renal cell carcinoma.
Lee-Ying R; Lester R; Heng D
Int J Urol; 2014 Sep; 21(9):847-55. PubMed ID: 24862210
[TBL] [Abstract][Full Text] [Related]
7. Comorbidity and frailty assessment in renal cell carcinoma patients.
Courcier J; De La Taille A; Lassau N; Ingels A
World J Urol; 2021 Aug; 39(8):2831-2841. PubMed ID: 33616708
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for metastatic renal cell cancer.
Verbaeys C; Hoebeke P; Van Belle S; Rottey S
Acta Clin Belg; 2010; 65(2):115-21. PubMed ID: 20491361
[TBL] [Abstract][Full Text] [Related]
9. Kidney cancer in the elderly.
Kirkali Z
Urol Oncol; 2009; 27(6):673-6. PubMed ID: 19879478
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.
Noe A; de Bruijn RE; Blank C; Horenblas S; Haanen J; Bex A
World J Urol; 2016 Aug; 34(8):1067-72. PubMed ID: 26832350
[TBL] [Abstract][Full Text] [Related]
11. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies.
Thomas JS; Kabbinavar F
Crit Rev Oncol Hematol; 2015 Dec; 96(3):527-33. PubMed ID: 26299335
[TBL] [Abstract][Full Text] [Related]
12. Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.
Tanaka N; Mizuno R; Shirotake S; Ito K; Yasumizu Y; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Urol Oncol; 2016 Jul; 34(7):293.e17-25. PubMed ID: 27040380
[TBL] [Abstract][Full Text] [Related]
13. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
Bellmunt J; Eisen T; Szczylik C; Mulders P; Porta C
BJU Int; 2011 Apr; 107(8):1190-9. PubMed ID: 21078050
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy in renal cell carcinoma: A booming clinical research].
Baize N; Bigot P
Prog Urol; 2018 Mar; 28(3):137-145. PubMed ID: 29339141
[TBL] [Abstract][Full Text] [Related]
15. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
16. [Medical treatment of renal cell carcinoma].
Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G
Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081
[TBL] [Abstract][Full Text] [Related]
17. Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma.
van den Brom RR; van Es SC; Leliveld AM; Gietema JA; Hospers GA; de Jong IJ; de Vries EG; Oosting SF
Cancer Treat Rev; 2016 May; 46():63-72. PubMed ID: 27123882
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
19. [Neoadjuvant targeted therapies in renal cell carcinoma].
Bigot P; Pignot G; Bernhard JC; Patard JJ
Prog Urol; 2016 Mar; 26(3):191-6. PubMed ID: 26781767
[TBL] [Abstract][Full Text] [Related]
20. Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies.
Cholley T; Thiery-Vuillemin A; Limat S; Hugues M; Calcagno F; Mouillet G; Anota A; Nerich V
Clin Genitourin Cancer; 2019 Feb; 17(1):e227-e234. PubMed ID: 30502046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
